[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641258":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":32,"locations":33,"responsibleParty":55,"collaborators":32,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":32,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":32,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":32,"overallStatus":36,"whyStopped":32,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Iuliu Hatieganu University of Medicine and Pharmacy","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Propofol and fentanyl sedation","ACTIVE_COMPARATOR","This group receives procedural sedation and analgesia acording to ASA guidlines with propofol and fentanyl alone.",[13],"Drug: Sedation using combination of Propofol and Fentanyl.",{"label":15,"type":16,"description":17,"interventionNames":18},"Propofol plus fentanyl plus lidocaine","EXPERIMENTAL","This group receives a procedural sedation and analgesia with propofol and fentanyl, combined with a 1.5 mg\u002Fkg slow bolus of lidocaine followed by an intravenous lidocaine infusion of 1 mg\u002Fkg\u002Fh for 24 hours (PF-L group).",[19],"Drug: Sedation using combination of Propofol and Fentanyl and lidocaine",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Sedation using combination of Propofol and Fentanyl.","Group 2 received PSA with propofol and fentanyl alone (PF group).",[9],[27],"Sedation using combination of propofol, fentanyl and lidocaine infusion",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Sedation using combination of Propofol and Fentanyl and lidocaine","Group 1 received a procedural sedation and analgesia (PSA) with propofol and fentanyl, combined with a 1.5 mg\u002Fkg slow bolus of lidocaine followed by an intravenous lidocaine infusion of 1 mg\u002Fkg\u002Fh for 24 hours (PF-L group)",[15],null,[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"\"Prof. Dr. Octavian Fodor\" Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania","RECRUITING","Cluj-Napoca","Cluj","400394","Romania","RO",{"type":43,"coordinates":44},"Point",[45,46],23.6,46.76667,{"lat":46,"lon":45},[49],{"name":50,"role":51,"phone":52,"phoneExt":53,"email":54},"Sergiu Sargarovschi","CONTACT","0757677855","+40","sergiu.sargarovschi@gmail.com",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Șargarovschi Sergiu","assistant professor","100641258","the-impact-of-anaesthesia-on-inflammation-and-netosis-in-hepatocellular-carcinoma-resection-100641258",false,"NCT07657897","The Impact of Anaesthesia on Inflammation and NETosis in Hepatocellular Carcinoma Resection","Inclusion Criteria:\n\n* patients with a hepatocellular carcinoma suitable for RFA\n* tumor measuring up to 3 cm in diameter\n* ASA I, II, or III\n\nExclusion Criteria:\n\n* candidates for surgery\n* chronic immunosuppressive medication\n* contraindications to any of the study medications\n* patients with psychiatric disorders\n* autoimmune disorders\n* corticosteroid-dependent bronchial asthma\n* congenital or acquired coagulation disorders\n* HIV-positive patients\n* pregnant women\n* antiarrhythmic therapy","ALL","18 Years","80 Years",{"count":69,"type":70},100,"ESTIMATED","INTERVENTIONAL",[73],"NA","According to recent literature, liver disease causes approximately 2 million deaths annually; 1 million are attributed to the complications of cirrhosis, while the remaining deaths are caused by hepatocellular carcinoma (HCC). The latter currently ranks 16th among the leading causes of death worldwide.\n\nCurrent research focuses on investigating novel therapeutic modalities, optimizing surgical and anesthetic practices, and identifying biological biomarkers to predict disease progression and severity. In this study, we address radiofrequency ablation (RFA) with the goal of improving periprocedural prognosis, recurrence rates, and overall survival. Specifically, we will quantify the expression of NETosis, a relatively novel biomarker with potential therapeutic and prognostic value in HCC progression. NETosis is a regulated form of cell death through which granulocytes release decondensed chromatin and various proteases into the extracellular space, forming a web-like meshwork known as neutrophil extracellular traps (NETs). These structures are actively involved in hepatic tumorigenesis by promoting tumor growth and metastasis.\n\nRecent clinical data reveal that NETs play a key role in:\n\nLocal tumor progression\n\nThe incidence of hepatic metastasis\n\nDirect modulation of the immune response\n\nHepatic ischemia-reperfusion injury\n\nSeveral recent studies demonstrate that the in vivo blockade of NETosis reduces tumor recurrence, mitigates the pro-inflammatory state, and serves as a valuable prognostic indicator in advanced liver disease \\[2,3,4\\]. To suppress NETosis expression and ultimately lower recurrence rates, our protocol evaluates the intraprocedural administration of 1% lidocaine followed by a continuous postoperative intravenous lidocaine infusion.",[76,77,78],"Hepato Cellular Carcinoma (HCC)","Sedation and Analgesia","Ablation Techniques","2026-06-13",{"date":81,"type":82},"2026-06-18","ACTUAL",{"date":84,"type":82},"2024-11-12",{"date":86,"type":70},"2026-11-12",{"name":5,"class":6},1]